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Captopril enhances aminoglycoside nephrotoxicity in potassium-
depleted rats. We demonstrated that potassium depletion significantly
increased gentamicin nephrotoxicity in Sprague-Dawley rats (100
mg.kg1day). To determine whether this enhanced toxicity was
mediated by renin secretion, we evaluated the effect of a converting
enzyme inhibitor in this model. When we administered the combination
of captopril (100 mg.kg.day') and gentamicin in potassium-depleted
rats, we observed a surprising and significant adverse effect of this
combination on the clearances of inulin (C1) and PAH (CPAH) and renal
blood flow (RBF). Pretreatment with indomethacin significantly im-
proved C1 and CPAH, and potassium repletion abolished this effect
entirely. In potassium-depleted animals that received both gentamicin
and captopril, the intra-arterial administration of imidazole, a throm-
boxane synthetase inhibitor, significantly reduced urinary TXB2 excre-
tion and significantly improved RBF and C1,, in vivo. In the same group
of animals, administration of the kallikrein antagonist aprotinin also
significantly increased both RBF and Ci,,. To measure total renal
thromboxane B2 production (TXB2), we perfused kidneys ex vivo with
cell-free perfusate. Three groups of animals were studied: potassium-
repleted control animals, potassium-depleted control animals, and
potassium-depleted animals treated with gentamicin alone, captopril
alone, or the combination of gentamicin and captopril. We measured
TXB2 in renal venous effluent by radioimmunoassay. Ex vivo perfused
kidneys from potassium-depleted control animals produced signifi-
cantly more TXB2 than potassium-repleted controls. Kidneys from
potassium-depleted animals that received both gentamicin and captopril
produced significantly greater amounts of TXB2 than did kidneys from
potassium-depleted animals treated with captopril alone, gentamicin
alone, or control potassium-depleted kidneys. The administration of
imidazole cx vivo at a rate equivalent to in vivo administration (10
/LM/min) reduced TXB2 production by potassium-depleted kidneys that
received the combination of gentamicin and captopril to that of
potassium-repleted control kidneys. These results suggest that the
deleterious effect of captopril in potassium-depleted rats that received
gentamicin is due at least in part to kinin-stimulated renal TXB2
production.
Le captopril accrolt Ia néphrotoxicité des amino-glycosides chez des rats
déplétes en potassium. Nous avons démontré que Ia ddplétion potas-
sique augmentait significativement la néphrotoxicité de Ia gentamicine
chez des rats Sprague-Dawley (100 mg/kg Vjour'). Afin de determiner
Si cette toxicité accrue était médiée par une sCcrétion de rénine, nous
avons évalué l'effet d'un inhibiteur de l'enzyme de conversion dans ce
modèle. Quand nous avons administré une association de captopril (100
mgIkg/jour') et de gentamicine chez des rats déplétés en potassium,
nous avons observe un effet adverse surprenant et significatif de cette
association sur les clearances de l'inuline (C10) et du PAH (CPAH) et sur
Ic debit sanguin renal (RBF). Le prdtraitement avec de l'indométacine
a signifleativement améliord C1,, et CPAH, et Ia réplétion potassique a
aboli cet effet entiérement. Chez des animaux déplétés en potassium qui
ont recu a la fois de la gentamicine et du captopril, l'administration
intra-artérielle d'imidazole, un inhibiteur de la thromboxane synthé-
tase, a réduit significativement I'excrCtion urinaire de TXB2 et a
améliorC significativement RBF et C10 in vivo. Dans le méme groupe
d'animaux, I'administration d'apronitine, un antagoniste de kallikréine,
a aussi significativement accru RBF et C,,,. Afin de mesurer la produc-
tion rénale totale de thromboxane B2 (TXB2), nous avons perfuse des
reins cx vivo avec un perfusat acellulaire. Trois groupes d'animaux ont
été etudiés: des animaux contrôles répldtés en potassium, des animaux
contriles déplétCs en potassium, et des animaux dépletés en potassium
traités avec de la gentamicine seule, du captopril seul, ou l'association
de gentamicine et de captopril. Nous avons mesuré TXB2 dans l'effluent
veineux renal par radioimmunoessai. Les reins perfusés ex vivo des
animaux contrôles déplétés en potassium ont produit significativement
plus de TXB2 que les contrôles rCpletés en potassium. Les reins des
animaux ddplétés en potassium qui ont recu a Ia fois Ia gentamieine et
Ic captopril ont produit significativement plus de TXB2 que les reins
d'animaux déplétés en potassium traités avec le captopril seul, Ia
gentamicine seule, ou que les reins de contniiles déplCtCs en potassium.
L'admimstration d'imidazole ex vivo a une vitesse équivalente a une
administration in vivo (10 rM/min) a rCduit la production de TXB2 par
les reins déplétés en potassium ayant recu l'association de gentamicine
et de captopril a celle des reins contriles replétés en potassium. Ces
résultats suggerent que l'effet dëlétere du captopril chez les rats
déplétés en potassium ayant recu de la gentamicine est dil, au moms en
partie, a une production de TXB2 stiniulée par les kinines.
Gentamicin nephrotoxicity continues to be one of the most
common forms of hospital-acquired acute renal failure. Many
factors enhance the nephrotoxicity of gentamicin, including age
[1, 2], renal insufficiency [1—5], volume depletion [6—8], con-
comitant diuretic therapy [9—141, and metabolic acidosis [15,
16]. Potassium depletion is common in these clinical settings
also. In preliminary studies, we determined that potassium
depletion enhances gentamicin nephrotoxicity in rats [17].
Subsequently, Brinker et al confirmed these observations in
dogs [181. Furthermore, Niizato et al demonstrated that the
potassium salt, but not the sodium salt, of d-glucose-lactam had
a protective effect on aminoglycoside nephrotoxicity in rats
[19].
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Potassium depletion could contribute to the decline in
glomerular filtration rate by stimulating renin release and angi-
otensin II production. Therefore, we postulated that treatment
with the angiotensin-converting enzyme inhibitor, captopril,
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Weight
Plasma
Na K
Muscle
Na
Diet g mEqiliter Eq/g wet wt
K reple-
tion 303 8 148.8 1.1 4.5 .3 25.2 2.3 111.3 1.7
N 80 80 80 30 30
K deple-
tion 300 6 147.6 1.2 2.4 .2 45.1 3.6 90.5 3.9
N 211 211 211 35 35
P NS NS <0.001 <0.001 <0.001
might prevent the deleterious effects of potassium depletion on
gentamicin nephrotoxicity. Surprisingly, captopril exacerbated
gentamicin nephrotoxicity markedly in potassium-depleted rats
[20—22]. The present study explores the mechanism of this
potentially important drug interaction.
Methods
Potassium depletion and repletion
We housed male Sprague-Dawley rats weighing 250 to 350 g
in metabolic cages. All animals were injected with furosemide
(50 mg/kg s.c.) on Day —7. Potassium-depleted animals were
fed a potassium-free diet (ICN #902902, Nutritional Biochemi-
cals, Cleveland, Ohio, USA) and were given 1% saline and 5%
sucrose drinking water for 7 days. Potassium-repleted animals
were fed the potassium-free diet also, but received a potassium
supplement of 5 mEq/dl in their drinking water. We performed
metabolic balance studies for the 7 days prior to study. Each
day, we weighed all rats and measured plasma sodium and
potassium concentrations in blood drawn from the tail. After 7
days, we measured plasma calcium and magnesium concentra-
tions in 10 potassium-depleted and 10 potassium-repleted rats.
In 35 potassium-depleted and 30 potassium-repleted animals,
we determined muscle sodium and potassium content (Table 1).
In these animals, we removed the gastronemius muscle, deter-
mined its wet wt, and digested it then in 5 ml of concentrated
nitric acid. An aliquot was removed to determine sodium and
potassium concentrations.
Effect of converting enzyme inhibition on gentamicin
nephrotoxicity in potassium-depleted rats
We studied a total of 90 rats divided into three groups (Fig. 1).
All animals were injected daily with gentamicin (100 mg/kg
s.c.). The first group of animals was potassium repleted, the
second group was potassium depleted, and the third group was
potassium depleted, but received the converting enzyme inhib-
itor, captopril, (100 mgkg1day s.c.) with gentamicin. We
determined the dose of captopril by performing in vivo dose
response curves to a pressor infusion of angiotensin I in
anephric animals. At 100 mg/kg, captopril blocked the 10 mm
Hg increase in mean arterial blood pressure produced by the
angiotensin I infusion. After 3 days of therapy, we sacrificed
one animal from each group for renal histology. Kidneys were
drip fixed with 6.25% gluteraldehyde in 0.1 M sodium cacodyl-
ate buffer. One micron sections were stained with toluidine
blue. In an additional five animals that received gentamicin and
Days
Fig. 1. Effects of potassium depletion and captopril on gentamicin
nephrotoxicity. Three groups of 30 animals received daily gentamicin
(100 mg/kg). Plasma creatinine concentration rose significantly faster in
potassium-depleted animals receiving gentamicin when compared with
potassium-repleted controls. Co-treatment with captopril not only
failed to prevent this increase in creatinine concentration in potassium-
depleted animals, but also produced an increase in mortality. The
number of survivors is indicated in parentheses. Values represent mean
SEM. Symbols are: 0, K-depleted plus captopril animals; O,
K-depleted animals; •, K-repleted animals.
captopril, we studied mean arterial blood pressure following the
captopril injection. Each day, one of these five animals was
anesthetized with ether and placed into a restraining cage
following the insertion of a femoral artery catheter. Intra-
arterial blood pressure was monitored for 6 to 8 hr following the
s.c. injection of captopril.
Plasma creatinine concentration, renal clearance studies, and
excretory function
Plasma creatinine concentration increased most rapidly in
potassium-depleted animals that received both captopril and
gentamicin (Fig. 1). Therefore, we measured plasma creatinine
concentration and performed clearance studies in 201 rats after
only 1 day of therapy to determine the early functional changes
in this model (Fig. 2). Fifty animals were potassium repleted
and 166 animals were potassium depleted (151 underwent
clearance studies). On Day 0, potassium-repleted animals re-
ceived the gentamicinlcaptopril vehicles (5% dextrose in wa-
ter), gentamicin (100 mg/kg s.c.), or gentamicin plus captopril
(100 mg/kg s.c.). In the potassium-depleted groups, animals
received either gentamicin alone, captopril alone, indomethacin
alone (5 mg/kg i.p. on both Day —1 and Day 0), or combinations
of these drugs. Renal clearance studies were performed 24 hr
following these injections (Day 1). Plasma creatinine concen-
tration was determined in tail blood obtained prior to injection
on Day 0 and in the first arterial blood sample obtained 24 hr
later on Day 1.
On Day 1, rats were anesthetized with mactin (100 mg/kg i.p.)
to prepare them for renal clearance studies. We cannulated the
femoral vein to infuse '4C-inulin and 3H-p-amino hippurate, the
left iliac artery to monitor arterial blood pressure and to obtain
arterial blood samples, and the bladder to obtain urine for
Table 1. Plasma and muscle Na and K in potassium-repleted and
-depleted rats
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Fig. 2. Experimental design for hemodynamic and clearance studies.
Potassium-repleted animals are indicated by solid arrows and
potassium-depleted animals by open arrows. The vertical arrows at the
bottom from Day —7 to Day 0 indicate the administration of the various
drugs; those on Day 1 indicate the type of studies performed. All rats
received furosemide on Day —7. Indomethacin (I) was given on Day —
(asterisks) and Day 0. Gentamicin (0), vehicle (D5W), and captopril (C)
were given on Day 0. On Day 1, renal clearance studies were performed
in 151 of the 166 potassium-depleted animals and 50 potassium-repleted
animals. Renal hemodynarnic studies were performed on Day 1 in 30
G+C animals. In these animals, renal blood flow was measured before
and after the intrarenal artery administration of the thromboxane
synthetase inhibitor, imidazole (Im), and the kallikrein antagonist,
aprotinin (Ap). Isolated perfused kidney studies (IPK) were performed
in 15 potassium-repleted controls, 15 potassium-depleted controls, six
potassium-depleted animals treated with 0 alone, six potassium-
depleted animals treated with C alone, and ten potassium-depleted
animals treated with the combination of G+C. In three additional
kidneys from potassium-depleted animals treated with G+C, Im was
infused into the renal artery during ex vivo perfusion. N = number of
animals.
Renal hemodynamic studies
We studied renal blood flow, C1. and CPAH in 30 of the 40
potassium-depleted animals that received both gentamicin and
captopril. Twenty-four hr following injection, the animals were
anesthetized with mactin and catheters were placed in the left
renal vein, left renal artery, left ureter, and bladder as described
previously [23]. We measured renal blood flow (RBF) by one of
fifteen rats, we determined RBF by measuring CPAH and
correcting for renal PAH extraction and hematocrit. In addition
to these measurements of RBF, we measured C1, mean arterial
blood pressure, and the urinary excretion of thromboxane B2
before and during the intrarenal arterial administration of either
the thromboxane synthetase inhibitor, imidazole, (10 M/min)
or the kallikrein inhibitor, aprotinin, (1,000 kinin inhibitory
units/kg/mm).
Ex vivo perfused kidneys
6 We measured thromboxane B2 production (TXB2) by cx vivo
perfused kidneys from 15 potassium-depleted and 15 potassium-
repleted controls. We measured TXB2 production by ex vivo
perfused kidneys from potassium-depleted animals that re-
ceived gentamicin alone (N = 6), captopril alone (N = 6), or the
combination of gentamicin and captopril (N = 10) 24 hr prior to
study. In three other potassium-depleted animals that received
both gentamicin and captopril, we measured renal venous TXB2
production while infusing the thromboxane synthetase inhibi-
tor, imidazole, into the renal artery cannula during cx vivo
perfusion at 10 LM/min.
We prepared the left kidney for cx vivo perfusion by anes-
thetizing rats and inserting a polished metal cannula into the left
renal artery. We ligated the renal artery around the cannula and
perfused the kidney immediately with warmed (32°C) and
oxygenated (95% 02, 5% C02) Kreb's-Henseleit solution con-
taining 1 m calcium. The perfusate was delivered by a
peristaltic pump at a rate designed to maintain a perfusion
pressure of approximately 60 to 70mm Hg (8 to 10 mI/mm). The
left renal vein and ureter were cannulated and all small vascular
branches ligated. The entire kidney was removed en bloc with
catheters in place and suspended in a warming chamber.
Three renal venous samples were collected on ice during a
30-mm control period. Thereafter, we injected 1 j.g boluses of
bradykinin into the left renal artery every 30 mm to stimulate
eicosanoid production [24—30]. Samples of the venous effluent
were collected on ice every 30 mm throughout the remainder of
the experiment (4 hr). Five ml aliquots of the renal venous
samples were removed and stored at —70°C until TXB2 was
measured by radioimmunoassay.
Analytical techniques
We measured 3H and 14C activity in plasma and urine with an
Iso-Cap 300 liquid scintillation system (Nuclear Chicago, Elk
Grove Village, Illinois, USA) using Aquasol II (New England
Nuclear, Boston, Massachusetts, USA). We analyzed plasma
and urine sodium and potassium with a lithium internal standard
flame photometer (Instrumentation Laboratories, Inc. Lexing-
ton, Massachusetts, USA), and UOsm and Osm with a vapor
pressure osmometer (Wescor, Inc. Logan, Utah, USA). We
determined creatinine colorimetrically using a modified Jaffe
reaction [31].
Radioimmunoassays
TXB2 was extracted by passing samples through C18 columns
(Sep-Pak C18 cartridges, Waters Associates, Millford, Massa-
chusetts, USA), washing with distilled water, and eluting sam-
ples with acetonitrile. The samples were dried at 35°C with dry
nitrogen and then resuspended in buffer and assayed for TXB2
by radioimmunoassay. Reagents were purchased from Seragen,
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clearance studies. The animals were allowed to equilibrate for I
hr and the clearances of inulin (C1) and PH (CPAH) were
determined during three 30-mm urine collections.
two methods. In fifteen rats, we measured renal blood flow
directly using a 2 mm internal circumference electromagnetic
flow probe (Carolina Medical Electronics, King, North Caro-
lina, USA) placed around the left renal artery. In the other
I,
p
1'
a' ..
0
-t
Captopril enhances gentamicin nephrotoxicity in rats 121
Fig. 3. Day 3 photomicrographs. One micron sections of renal cortex from potassium-depleted animals that received daily D5W (A), gentamicin
(B), or the combination of gentamicin and captopril (C) for 3 days. In all groups, many vacuoles consistent with potassium depletion are apparent.
In animals treated with gentamicin (B and C), there are increased numbers of densely stained lysosomes consistent with gentamicin therapy. There
is no evidence of massive tubular necrosis to explain the impairment in renal function in the G+C animals (C). Sections are stained with toluidine
blue. (x800)
Inc. (Boston, Massachusetts, USA). Antiserum for TXB2 was
generated in rabbits using immunogen complexed to bovine
serum albumin. The antibody to TXB2 demonstrated 50%
binding at a final titer of 1:35,000; cross-reactivity to other
eicosanoids at 50% B/B0 was < 0.1%. 3H TXB2 was added to
each sample prior to extraction and RIA values were corrected
for the recovery of tritium following extraction. With this
extraction procedure, 60 to 70% of TXB2 was recovered.
Samples were incubated at 4°C for 20 hr with a mixture of
antisera to TXB2 and a known amount of 3H TXB2 (specific
activity of approximately 110 to 150 CiImM). We adsorbed free
TXB2 with dextran-coated charcoal and measured 3H remaining
in the supernatant with a liquid scintillation counter. The
unknowns, corrected for 3H recovery from the extraction
procedure, were compared to the standard curve in which the
logarithm of the concentration was plotted against the logit of
the B/B0 value. The results are expressed as pg/mm of TXB2.
Statistics
Values for plasma creatinine and all clearance studies repre-
sent means standard errors of the mean. We evaluated
clearance and electrolyte data by an analysis of variance.
Differences between means were calculated using Duncan's test
for all groups. In the hemodynamic studies, significance was
determined by paired t test.
Results
Potassium depletion
A single injection of furosemide produced a 2.4 0.4 mEq
potassium loss and a 15 6 g decrease in body wt for all rats.
Net negative potassium balance plateaued by Day —4 at 2.9
0.1 mEq. After 7 days of the potassium-depleted diet (Day 0),
there was no significant difference in body wt between
potassium-depleted and potassium-repleted rats (Table 1). Ta-
ble 1 compares also the plasma concentration and muscle
content of sodium and potassium determined in potassium-
depleted and potassium-repleted animals. Potassium-depleted
animals had a significantly lower plasma potassium. Plasma
sodium concentration was not significantly changed. Muscle
potassium was significantly lower and muscle sodium was
significantly higher in potassium-depleted rats. Plasma calcium
and magnesium concentrations in potassium-depleted animals
were not significantly different from those of potassium-
repleted animals (8.1 0.3 vs. 8.3 0.6 mg% of calcium and
2.1 0.1 vs. 2.3 0.2 mg% of magnesium).
Gentamicin toxicity in potassium-depleted animals
Figure 1 demonstrates plasma creatinine concentration in
potassium-repleted and potassium-depleted animals that re-
ceived daily injections of gentamicin, as well as potassium-
depleted animals that received the combination of gentamicin
and captopril. In the potassium-repleted group, daily gentami-
cm administration was associated with a progressive increase in
plasma creatinine concentration. The values on Day 5 were
significantly greater than those on Day 1 (P < 0.05). Of the 30
animals in this group, 25 survived for 10 days. In the potassium-
depleted animals, daily injections of gentamicin increased
plasma creatinine concentration significantly faster than in the
potassium-repleted animals. By Day 2, plasma creatinine con-
centration was already significantly increased above its baseline
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creatinine concentration in potassium-depleted animals that
received both gentamicin and captopril was significantly greater
than in potassium-depleted animals that received gentamicin
alone (P < 0.05). Survival in this group was even worse in that
only 13 of the original 30 rats were alive after five injections.
The mean arterial blood pressure of the five conscious
potassium-depleted rats that received the combination of
gentamicin and captopril fell an average of 6 mm Hg during the
6 to 8 hr following the injection of captopril (from 108 4 to 102
4 mm Hg). Animals that received the captopril diluent
experienced no change in blood pressure. Mean arterial blood
pressure was measured in the anesthetized animals undergoing
clearance studies on Day 1. Mean arterial blood pressure was
112 5 in the 33 potassium-depleted animals that received
gentamicin alone and 106 4 in the 40 animals that received the
combination of gentamicin and captopril 24 hr prior to study.
While blood pressure was reduced by captopril therapy, these
differences are not statistically significant (unpaired t test).
Figures 3A, B, and C demonstrate the morphologic appear-
ance of Day 3 kidneys removed from potassium-depleted rats
(3A), potassium-depleted rats that received gentamicin (3B), or
potassium-depleted rats that received the combination of
gentamicin and captopril (3C). In all groups of animals, there
are many vacuoles typical of potassium depletion. An increased
number of densely staining lysosomes consistent with amino-
glycoside toxicity are apparent in kidneys from gentamicin-
treated animals (3B and C). There was no evidence of massive
tubular necrosis in any of the groups that might explain the
significant reduction in RBF and C1, observed in the combined
treatment group (3C).
As demonstrated in Figure 4, plasma creatinine concentration
on Day 0 tended to be lower in the potassium-repleted animals
(0.6 0.3) when compared with potassium-depleted animals
(1.0 0.2), although this difference was not statistically signif-
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r1
I3.0
2.0
1.0
NS
ThI1I1I
<0.01 <0.01
I II
011 oh oh oh 0 1
D5W G G+C
30.0
15.0
G G+C G+l
Fig. 6. PAH clearance 24 hr following injection (Day 1). Potassium-
depleted animals are indicated by open bars () and potassium-repleted
animals by solid bars (. The abbreviations are the same as Fig. 2. P
values are indicated where significant by analysis of variance.
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Fig. 4. Plasma creatinine concentration before (Day 0) and after (Day
1) injection. Solid bars ( represent potassium-repleted animals and
open bars () potassium-depleted animals. These data include plasma
creatinine concentrations from the 90 animals in Fig. 1 as well as the 201
animals undergoing clearance studies in Fig. 2. The group identifica-
tions below the bars are the same as Fig. 2. Values are means SEM.
P values are given where significant by analysis of variance,
<0.05
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Fig. 5. inulin clearance 24 hr following injection (Day 1). Potassium-
depleted animals are indicated by open bars () and potassium-repleted
animals by solid bars (). The abbreviations are the same as Fig. 2. P
values are indicated where significant by analysis of variance.
value (P < 0.02). The increase in plasma creatinine concentra-
tion after two injections in this potassium-depleted group was
also significantly greater than the plasma creatinine concentra-
tion of potassium-repleted animals at Day 2 (P < 0.05). Mor-
tality was also greater in this potassium-depletel group. Of the
initial 30 animals, only 12 were alive after eight injections.
The addition of captopril did not prevent the more rapid
increase in plasma creatinine concentration observed in potas-
sium-depleted animals receiving daily gentamicin. Surprisingly,
co-treatment with captopril produced a significant increase in
plasma creatinine concentration in the potassium-depleted ani-
mals treated with gentamicin. By Day 3, the increase in plasma
icant. Treatment with a single dose of gentamicin increased
plasma creatinine concentration only slightly in potassium-
depleted animals and not at all in the potassium-repleted group.
The combination of gentamicin and captopril increased plasma
creatinine concentration markedly in potassium-depleted ani-
mals. Potassium repletion or the coadministration of indometh-
acm prevented this increase in plasma creatinine concentration
totally. Neither indomethacin nor captopril alone had any effect
on potassium-depleted animals that did not receive gentamicin.
In these same groups of animals, we performed clearance
studies 24 hr following the injection of either D5W, gentamicin,
captopril, indomethacin, or combinations of the various drugs.
As demonstrated in Figure 5, Cth was slightly, but not signifi-
cantly, reduced by potassium depletion alone (10.1 0.6 vs.
10.8 0.8 rnlminkg'). A single injection of gentamicin into
potassium-depleted animals significantly reduced C1 (P <
0.02). A single injection of gentamicin into potassium-repleted
animals had no effect. The coadministration of gentamicin and
captopril to potassium-depleted rats produced the most signif-
icant reduction in C1. Potassium repletion abolished this effect
totally. Treatment with indomethacin ameliorated the deleteri-
ous effect of combined captopril and gentamicin administration
in potassium-depleted animals. Indomethacin alone improved
Cth slightly in potassium-depleted animals that did not receive
gentamicin, but this effect was not significant. Captopril alone
had no effect. CPAH results were similar and are demonstrated
in Figure 6.
1
Fig. 8. Renal TXB2 production by ex vivo perfused kidneys. Potassium-
repleted control kidneys (•) and potassium-depleted control kidneys
(E) received D5W 24 hr prior to ex vivo perfusion. Potassium.depleted
kidneys that received gentamicin alone are indicated by the captopril
alone by , and the combination of gentamicin and captopril by 0.
Kidneys from potassium-depleted animals that received gentamicin and
captopril and were perfused with the thromboxane synthetase inhibitor,
imidazole (Tm), at 10 iM/min during ex vivo perfusion are indicated by
the broken line. Values represent mean SEM.
We evaluated the specific mechanisms of indomethacin's
beneficial effect by infusing imidazole, a thromboxane synthe-
tase inhibitor, into the renal arteries of 14 potassium-depleted
animals that received both gentamicin and captopril. Imidazole
infusion decreased the urinary excretion of TXB2 from 112.9
14.6 to 8.2 3.0 pg/mm (P < 0.001). As demonstrated in Figure
7, imidazole significantly improved C1 and RBF of potassium-
depleted rats that received gentamicin and captopril to approx-
imately 60% of normal levels. However, renal function was not
restored to normal totally. In order to evaluate whether in-
creased kinins were important to captopril's deleterious effect,
we infused aprotinin, a kallikrein antagonist, into the renal
arteries of 15 other animals from the same group. Like
imidazole, aprotinin significantly improved C1 and RBF (Fig.
7), but failed to restore renal function to normal levels.
The beneficial response to imidazole suggested that throm-
boxane may be an important vasoconstrictor in this model.
Therefore, we measured TXB2 production by ex vivo perfused
<0.02
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Fig. 7. Renal blood flow and C, of potassium-depleted animals 24 hr
following the injection of gentamicin and captopril. (El) The animals
that received intrarenal arterial infusion of imidazole (Tm) are indicated
by the dotted bars (us). Animals that received aprotinin (Ap) are
indicated by the slashed bars (). Values represent mean SEM. P
values are indicated where significant by paired t test.
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Table 2. Renal excretory function on Day P
D5W G
K+Db KR KD KR
Weight, g 292 12 296 16 298 8 318 15
Uj,,, diter/min/kg 54 20 48 20 142 30 106 30
U/Po,m 3.9 0.9 4.9 0.7 3.2 0.3 3.4 0.6
TCHZO/CO,m, % 1.2 0,2 1.0 0.1 1.9 0,2d 1.4 0.2
EFNa, % 0.7 0.4 0.3 0.1 3.3 1.6 1.2 0.5
UNaV, Eq/min/kg 7.2 1.6 4.4 1.2 25.7 2.17 15.6 2.1
UKV, p.Eqlmin/kg 1.6 1.4 7.8 1.4 0.7 0.2 7.9 1.6
N 15 18 33 17
a All studies were performed 24 hr following the injection of drug vehicle (D5W); gentamicin (G); captopril (C); indomethacin (I); or combinations
of the various drugs.
b Potassium-depleted animals are indicated by KD and potassium-repleted animals by KR.
P < 0.05 compared with KD or KR D5W controls.
d P < 0.025 compared with KD or KR D5W controls.
P < 0.005 compared with KD or KR D5W controls.
P < 0.01 compared with KD or KR D5W controls.
g P < 0.005 compared with KD or KR D5W controls.
N = number of animals.
kidneys from potassium-repleted controls, potassium-depleted
controls, and potassium-depleted rats that received gentamicin
alone, captopril alone, and the combination of gentamicin and
captopril. As shown in Figure 8, TXB2 production in the initial,
unstimulated renal venous samples was significantly higher in
the potassium-depleted groups than it was in the potassium-
repleted animals (P < 0.05). After 4 hr of bradykinin stimula-
tion, these differences were enhanced markedly such that at 230
mm, the kidneys from potassium-depleted rats produced signif-
icantly more TXB2 than kidneys from potassium-repleted rats
(P < 0.01). The administration of gentamicin and captopril to
potassium-depleted animals significantly increased renal TXB2
production when compared with potassium-depleted control
animals and potassium-depleted animals treated with gentami-
cm alone (P < 0.001) or captopril alone (P < 0.01). Potassium-
depleted animals that received captopril alone produced more
TXB2 than potassium-depleted control animals (P < 0.02) and
potassium-depleted animals treated with gentamicin alone (P <
0,05). The infusion of imidazole at 10 /LM/min to potassium-
depleted kidneys treated with the combination of gentamicin
and captopril reduced TXB2 production to that of potassium-
repleted control kidneys.
Excretory function is indicated in Table 2. Potassium deple-
tion alone increased sodium excretion and decreased potassium
excretion. Urine flow rate was increased in all animals that
received gentamicin, regardless of potassium balance or drug
combinations. Fractional sodium excretion was increased in all
potassium-depleted rats given gentamicin, but the effect was
most marked in those that received the combination of
gentamicin and captopril. Urine concentrating ability, ex-
pressed as the ratio of urine to plasma osmolality, was reduced
only in potassium-depleted rats that received gentamicin and
captopril. In summary, the changes in renal excretory function
were most marked in the potassium-depleted rats that received
gentamicin and captopril. These changes, however, are not
unique and would be expected in any animal with nonoliguric
acute renal failure.
Discussion
Potassium depletion is a commonly encountered clinical
condition that may contribute to renal failure of various causes
[32]. However, the mechanism by which potassium depletion
exacerbates acute renal failure remains unknown. Several au-
thors have demonstrated that potassium deficiency reduces or
redistributes renal blood flow in a variety of animal species
[33—35]. The renin-angiotensin and the prostaglandin-throm-
boxane systems could affect renal hemodynamic changes asso-
ciated with potassium deficiency. For example, potassium
depletion is a well-documented stimulus for increased renin
secretion [36—39]. Thus, one possible mechanism of enhanced
gentamicin nephrotöxicity in potassium-depleted animals might
be increased angiotensin II production. In studies of normoka-
lemic Munich-Wistar rats, Baylis, Rennke, and Brenner have
demonstrated that gentamicin decreases the glomerular ultrafil-
tration coefficient Kf [40]. Schor et al were able to ameliorate
the effect of gentamicin on Kf partially by suppressing angio-
tensin II production with either a saline infusion or the
coadministration of captopril [41]. Thus, in normal rats that are
not depleted of potassium, angiotensin II contributes to
gentamicin nephrotoxicity.
Because potassium depletion might enhance gentamicin
nephrotoxicity by stimulating renin release, we reasoned that
the administration of captopril, a converting enzyme inhibitor,
might be beneficial. To our surprise, captopril aggravated
greatly the deleterious effect of gentamicin on renal function in
potassium-depleted rats. Luft et al described a similar phenom-
enon with combined captopril and gentamicin therapy with
Sprague-Dawley rats that were normokalemic [42]. However,
the mechanism of enhanced toxicity was not addressed and
combined gentamicin and captopril treatment produced a 35
mm Hg fall in blood pressure at the time creatinine clearance
was found to be reduced (3 days after initiating therapy). In the
present study, this adverse effect of captopril was reversed by
pretreatment with indomethacin. Potassium deficiency was
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Table 2. Continued
C+C G+C+I
KD
G+I
KD
I
KD
C
KDKD KR
290 7
97 24
1.4 0.2c
3.4 0.5
28.2 4.6e
19.5 34C
0.4 0.3
40
288 12
126 39C
3.3 0.7
1.8 O.3
1.6 ÷ 0.7c
17.1 2.3
9.9 1.3
15
299 10
116 50
2.2 0.4c
2.3 0.8
7.2 6.0
16.6 2.5
0.8 0.3
20
312 12
140 32d
2.5 0.4
1.9 0.3'
2.4 Ø9C
19.2 2.0c
0.6 0.2
15
309 18
89 37
3.7 0.9
1.3 0.1
0.9 0.4
11.7 2.1
0.4 0.2
10
304 17
170 30g
2.2 0.3c
1.3 0.2
1.6 0•2d
22.9 2.6c
0.4 0.1
18
essential because potassium repletion abolished the effect of
captopril on gentamicin nephrotoxicity.
The beneficial effect of indomethacin and the deleterious
effect of potassium depletion might be explained by changes in
renal eicosanoid production. Beck and Shaw have demon-
strated increased TXB2 production and decreased PGE2 pro-
duction by renal papillary slices from potassium-depleted rats
[43]. Zusman and Keiser evaluated PGE2 biosynthesis by rabbit
renal medullary interstitial cells grown in culture, and demon-
strated that potassium deficiency decreases PGE2 synthesis in
that system [44]. Atallah et al reported that potassium-depleted
rats have decreased urinary excretion of PGE2 [45]. Linas and
Dickman have demonstrated that renal blood flow is reduced in
conscious rats subjected to potassium depletion. They reported
also that this reduction in renal blood flow is dependent on both
angiotensin and thromboxane [35]. Thus, potassium deficiency
appears to stimulate renal thromboxane production as well as
increase renin release.
In the present study, both potassium deficiency and captopril
were required to reduce markedly renal blood flow and func-
tion. Captopril blocks the angiotensin-converting enzyme that
converts angiotensin Ito angiotensin II, but this same enzyme
inactivates kinins also [46, 47]. Thus, captopril's deleterious
effect could be mediated indirectly by increased kinins. While
bradykinin has been demonstrated to have vasodilator proper-
ties in humans [48] and the dog [49—51], its effects in other
species, particularly the rat and rabbit, are confusing. In
hydronephrotic rabbits [24, 52] and rats [53], administration of
bradykinin produces renal vasoconstriction. In the isolated
perfused rat kidney, Guimaraes et al [54] have demonstrated a
bimodal renal vasodilator/vasoconstrictor effect of lysyl-
bradykinin.
Some authors have reported increased plasma kinin levels
following the administration of captopril [55—57], although this
has not been a universal finding [56, 58—64]. Others have
reported an increase in the urinary excretion of kinins following
captopril administration [65—68]. Captopril may have direct
renal effects as well. Gotoh et a! have reported that captopril
stimulates the release of renin, PGE2, TXB2, and kinins by the
ex vivo perfused hog kidney. All of these effects are blocked by
the kallikrein antagonist, aprotinin [69]. Because the ex vivo
perfused kidney has neither plasma kallikrein nor kininogin,
these data suggest that captopril stimulates directly the produc-
tion of kinins by the kidney and that these kinins are capable of
stimulating both renin release and thromboxane production.
Thus, the deleterious effect of captopril in the present study
could be mediated by the indirect effects of increased kinins.
Kinins are potent stimulators of renal eicosanoid production.
Bradykinin has been demonstrated to stimulate prostaglandin
and thromboxane production in other models of renal disease.
For example, bradykinin has been shown to stimulate TXB2
production in a model of unilateral ureteral obstruction in
rabbits [24—30], and we have demonstrated previously this
effect in rats [53]. Furthermore, Miyamoto, Koike, and
Yamazaki [70] demonstrated that captopril administration in-
creases urinary PGE2 and PGF2 excretion in spontaneously
hypertensive rats. In the present study, the improvement in
function achieved by the kallikrein inhibitor, aprotinin, which
decreases kinins [7 1—73], suggested strongly a role for kinin-
stimulated thromboxane production. Our data from the ex vivo
perfused kidney confirmed increased renal production of TXB2.
Renal blood flow and C increased during the intrarenal infu-
sion of imidazole, a thromboxane synthetase inhibitor, suggest-
ing that thromboxane was a physiologically important vasocon-
strictor in this model. Neither aprotinin nor imidazole returned
function to normal. However, these acute studies were per-
formed 24 hr after the administration of gentamicin and
captopril and irreversible renal injury may have occurred by
that time. Thus, 24 hr following drug administration, clearly,
other mechanisms are involved in the altered renal hemody-
namics of this model.
In summary, potassium depletion alone has been shown to
alter renal hemodynamics in conscious rats. We demonstrated
also that it enhanced the toxicity of gentamicin, a commonly
used nephrotoxic antibiotic. Captopril, a converting enzyme
inhibitor, augmented gentamicin nephrotoxicity markedly in
this model and increased renal TXB2 production. Captopril's
deleterious effect may have been mediated by the inhibition of
kininase II (converting enzyme), causing increased renal kinins
and kinin-stimulated thromboxane production. Because potas-
sium depletion, aminoglycoside use, and captopril administra-
tion are all common in patients, this model may be important
clinically. In addition, this study illustrates that the multiple
interactions between the kallikrein-kinin, renin-angiotensin,
and prostaglandin-thromboxane systems may be altered phar-
macologically in ways that produce unpredictable, and often
disastrous, effects on renal function.
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